First microRNA Targeted Drug Reaches Phase II Clinical Trial

by Chris on September 22, 2010

in News

Santaris Pharma A/S announced today that it has advanced miravirsen (SPC3649), a microRNA targeted drug for treatment of  Hepatitis C virus (HCV) infection into Phase 2 studies to assess the safety and tolerability of the drug.

Santaris Pharma A/S also received acceptance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA). In addition to the United States, the Phase 2a clinical trials will be conducted in the Netherlands, Germany, Poland, Romania, and Slovakia.

Miravirsen is a specific inhibitor of miR-122, a liver specific microRNA that the Hepatitis C virus requires for replication. Miravirsen is designed to recognize and sequester miR-122, making it unavailable to the Hepatitis C virus. As a result, the replication of the virus is effectively inhibited and the level of Hepatitis C virus is reduced.

In addition to miravirsen, Santaris Pharma A/S is developing other drugs targeting mRNAs and microRNAs both internally as well as in partnerships and collaborations with miRagen Therapeutics (cardiovascular diseases), Shire plc (rare genetic disorders), Pfizer (undisclosed therapeutic areas), GlaxoSmithKline (viral disease) and Enzon Pharmaceuticals (oncology).  (read more… )

It’s only a matter of time before the first microRNA therapeutic reaches the market.

Incoming search terms for this article:

{ 3 comments… read them below or add one }

Dr. Omar Bagasra February 2, 2012 at 10:56 am

I like to know where the miR-122 clinical trial stand currently. I heard that it went to Phase III. Please send me a link or an article that describes the details. Thank you.
B

Christoph February 2, 2012 at 12:01 pm
Tamás Baranyai April 14, 2012 at 3:34 pm

Hi Cristoph,
Do you have any informations about the clinical trials of mirnas? I mean, is there any list about it which is in phase I or II etc?
Thank you in advance!

Tamás

Leave a Comment

Previous post:

Next post: